Adamax vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Adamax | Exenatide |
|---|---|---|
| Mechanism | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |